PTOSB08a (0.6.70)
Approved for use through 11x00207 (0.80651-0.031)
U.S. Patent and Trademark Office; U.S. DEPARTENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless in contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10586269
Filing Date		2006-07-17
First Named Inventor	Wang	, et al.
Art Unit		N/A
Examiner Name	N/A	
Attorney Docket Number		UM-13022

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Issue Date Name of Patentee or Applic of cited Document			Relev	s,Columns,Lines where rant Passages or Relev es Appear	
	1	6608026		2003-08	i -1 9	Wang				
	2	7244851		2007-07	'-17	Cohen				
	3	6992063		2006-01	-31	Shi				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹			Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where rant Passages or Relev es Appear	
	1									
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ade	d butto	n. Add	
				FOREIG	IN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	04/005248	WO			2004-01-15	Novartis Pharma G	mbH		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10586269
iling Date		2006-07-17
irst Named Inventor Wang		, et al.
Art Unit		N/A
xaminer Name	N/A	
Horney Docket Number		LIM-13022

If you wis	h to a	dd additional Foreign Patent Document citation information please click the Add button Add							
		NON-PATENT LITERATURE DOCUMENTS Remove							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	ARNT, Christina R., et al., "Synthetic Smac/DIALO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ," The Journal of Biological Chemistry, Vol. 277, No. 46, November 15, 2002, pp. 44236-44243							
	2	ASSELIN, Eric, et al., "XIAP Regulates Akt Activity and Caspase-3-dependent Cleavage during Cisplatin-induced Apoptosis in Human Ovarian Epithelial Cancer Cells," Cancer Research 61, March 1, 2001, pp. 1862-1868							
	3	BUDIHARDJO, I., et al., "Biochemical Pathways of Caspase Activation Durin Apoptosis," Annu. Rev. Cell. Dev. Biol. 1999 15, pp. 269-90							
	4	CHAI, J., et al., "Structural Basis of Caspase-7 Inhibition by XIAP," Cell, Vol. 104, pp. 789-780, March 9, 2001.							
	5	DEVERAUX, Quinn L., "X-linked IAP is a direct inhibitor of cell-death proteases," Nature Vol. 388, July 17, 1997, pp. 300-304							
	6	DEVERAUX, Quinn L., et al., "Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases," The EMBO Journal., Vol. 18, No. 19, pp. 5242-5251 (1999)							
	7	DU, Chunying, et al., "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," Cell, Vol. 102, pp. 33-42, July 7, 2000							
	8	EKERT, Paul G., "DIABLO Promoles Apoplosis by Removing MIHA/XIAP from Processed Caspase 9," The Journal of Cell Biology, Vol. 152, No. 3, February 5, 2001, pp. 483-490.							
	9	FULDA, Simone, et al., "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo." Nature Medicine, Vol. 8, No. 8, August 2002, pp. 808-815							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10586269
Filing Date		2006-07-17
First Named Inventor Wang		, et al.
Art Unit		N/A
Examiner Name	N/A	
Attornov Docket Number		LIM-13022

10	HOLCIK, M., et al., "XIAP: Apoptotic brake and promising herapeutic target," Apoptosis 2001: 6: pp. 253-261.	
11	HOLCIK, Martin, et al., "Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell deah," Onogene (2000) 19, pp. 4174-4177	
12	HUANG, Yihua, et al., "Structural Basis of Caspase Inhibition by XIAP: Differential Roles of the Linker versus the BIR Domain," Cell, Vol. 104, pp. 781-790, March 9, 2001.	
13	KIPP, et al., "Molecular Targeting of Inhibitor of Apoptosis Proteins Based on Small Molecule Mimics of Natural Binding Partners," Biochemistry 2002, 41, pp. 7344-7349	
14	LaCASSE, Eric C., et al., "The inhibitors of apoptosis (IAPs) and their emerging role in cancer," Oncogene 17:3247 (1998)	
15	RIEDL, Stefan J., et al., "Structural Basis for the Inhibition of Caspase-3 by XIAP," Cell, ol. 104, pp. 791-800, March 9, 2001	
16	SALVESEN, Guy S., "IAP Proteins: Blocking the Road to Death's Door," Molecular Cell Biology, Vol. 3, June 2002, pp. 401-410	
17	SRINIVASULA, S., et al., "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis," Nature, Vol. 410, March 2001, pp. 112-116	
18	SRINIVASULA, S., et al., "Molecular Determinants of the Caspase-promoting Activity of Smac/DIABLO and Its Role in the Death Receptor Pathway, The Journal of Biological Chemistry, Vol. 275, No. 46, November 17, 2000, pp. 36152-36157	
19	SUN, C., et al., "NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP," Nature, Vol. 401, October 21, 1999, pp. 818-822	
20	TAKAHASHI, R., et al., "A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases," The Journal of Biological Chemistry Vol. 273 No. 14. April 3. 1998 no. 7787-7790	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JER/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10586269
Filing Date		2006-07-17
First Named Inventor	Wang	ı, et al.
Art Unit		N/A
Examiner Name	N/A	
Attornov Dooket Numb	or	LIM 13022

	21	TAMM, Ingo, et al., "Expression and Prognostic Significance of IAP-Family Genes in Human Cancers and Myeloid Leukemias," Clinical Cancer Research, Vol. 6, May 2000, pp. 1796-1803						
	22	WAGENKNECHT, Bettina, et al., "Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant gloma," Cell Death and Differentiation (1999) 6, pp. 370-376						
	23	WU, Geng, "Structural basis of IAP recognition by Smac/DIABLO," Nature, Vol. 408, December 2000, pp. 1008-1012						
	24	YANG, Lilling, et al., "Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a Novel Polyarginine-conjugated Smac peptide," Cancer Research 63, pp. 831-837, February 15, 2003						
If you \	wish to a	add additional non-patent literature document citation information please click the Add button Add						
	EXAMINER SIGNATURE							

Examiner Signature //Jeffrey Russel/ Date Considered 02/22/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ¹ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ² For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.